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VALORISATION	
 
Introduction	
An	abdominal	aortic	aneurysm	(AAA)	is	a	focal	dilatation	of	the	aorta	to	at	least	1.5	times	its	
normal	 diameter.	 The	 normal	 diameter	 of	 the	 infrarenal	 aorta	 is	 approximately	 20mm,	
therefore	an	aortic	diameter	of	30mm	or	larger	is	considered	being	aneurysmatic.	AAAs	are	
a	 significant	 health	 challenge	 with	 an	 estimated	 incidence	 of	 20	 –	 40	 cases	 per	 100,000	
population	per	year.		Its	more	commonly	seen	in	men	than	in	women,	with	a	prevalence	of	
1.3%	 to	 8.9%	 in	 males	 and	 1.0%	 tot	 2.2%	 in	 females.	 The	 prevalence	 of	 AAA	 in	 The	
Netherlands	 is	 approximately	90.000	among	people	older	 than	55	years	of	age.	 Important	
risk	factors	for	the	occurrence	of	AAA	are	gender,	age	and	smoking	habits.	
	
An	AAA	 is	a	progressive	disease,	which	 if	 left	untreated	eventually	 leads	 to	 rupture	of	 the	
aneurysm	with	massive	bleeding	and	consequently	death.	To	date,	AAAs	are	responsible	for	
1.3%	 of	 all	 deaths	 among	men	 aged	 between	 65-85	 years	 in	 developed	 countries.	 In	 The	
Netherlands,	each	year	approximately	850	persons	die	of	a	ruptured	aneurysm.	Since	AAAs	
generally	exists	without	symptoms,	the	AAA	related	mortality	is	probably	underestimated.		
	
The	 risk	 of	 rupture	 increases	 with	 the	 aneurysm	 diameter.	 Initial	 treatment	 of	 an	 AAA	 is	
aimed	 at	 preventing	 rupture.	 Because	 treatment	 itself	 also	 comes	with	 a	 risk	 of	mortality	
and	morbidity,	a	selected	treatment	policy	is	constructed.	A	preventative	aneurysm	repair	is	
indicated	when	the	threshold	diameter	 is	reached	(55mm	in	men	and	52mm	in	women),	 if	
rapid	aneurysm	growth	is	observed	(>5mm	per	6	months	in	AAAs	>40mm)	or	if	the	aneurysm	
becomes	 symptomatic	 (abdominal	 or	 back	 pain).	 AAAs	 are	 responsible	 for	 approximately	
7.000	hospital	admissions	yearly	in	The	Netherlands.		
	
Two	 modalities	 of	 AAA	 treatment	 are	 available;	 conventional	 open	 surgical	 repair	 or	
minimally	 invasive	 endovascular	 repair	 (EVAR).	 In	 open	 repair	 the	 aneurysmatic	 aorta	 is	
replaced	by	a	synthetic	graft.	This	treatment	requires	laparotomy,	clamping	of	the	aorta	and	
is	 accompanied	 by	 substantial	 blood	 loss,	 and	 is	 consequently	 associated	 with	 a	
perioperative	mortality	of	2%	to	5%	and	significant	morbidity.	In	EVAR	treatment	a	synthetic	
	
	 	 	
stentgraft	 is	 fed	 from	 femoral	 artery	 access	 in	 the	 groin	 through	 the	aorta	up	 to	 the	AAA	
neck	and	subsequently	unfolded,	excluding	the	aneurysm	sac	from	blood	flow	and	pressure.	
Initially,	 EVAR	was	 considered	 to	 be	 an	 alternative	 treatment	 for	 those	 AAA	 patients	 not	
suitable	 for	 open	 repair	 due	 to	 severe	morbidities.	Meanwhile,	 EVAR	 has	 proven	 to	 be	 a	
feasible	and	safe	technique,	showing	decreased	mortality	and	morbidity	rates	compared	to	
conventional	 open	 treatment.	 EVAR	 now	 has	 become	 the	 treatment	 of	 preference	 for	
patients	with	infrarenal	AAA.				
	
Despite	the	promising	results	of	EVAR	perioperatively	and	in	the	short-term,	complications	
unique	for	endovascular	treatment	cause	EVAR	to	be	less	beneficial	in	the	longer	term.	Also,	
a	 substantial	 proportion	 (40%)	 of	 AAA	 patients	 that	 require	 repair	 fall	 outside	 stringent	
anatomic	 criteria	 that	 make	 treatment	 with	 commercially	 available	 stentgrafts	 suitable.		
Improvement	 of	 EVAR	 treatment	 is	 necessary	 to	 enhance	 outcomes	 of	 AAA	 patients.	 The	
technology	 of	 EVAR	 is	 a	 dynamic	 ever-changing	 endeavour.	 The	 challenge	 is	 to	 decrease	
complications	and	reinterventions,	while	safely	 treating	more	complex	anatomy,	especially	
those	cases	unfit	for	open	repair.	In	the	mean	time	hold	dear	to	resource-effective	strategies	
that	 do	 not	 include	 technically	 complex	 and	 costly	 interventions	 when	 they	 are	 not	
necessary.	 Both	 patients	 and	 society	 as	 a	 whole	 benefit	 from	 simply	 applicable	 and	
affordable	 techniques	 for	 AAA	 repair.	 Well-designed	 registries	 that	 closely	 monitor	 the	
performance	of	new	graft	designs	and	new	endovascular	techniques	are	therefore	crucial	in	
making	balanced	judgement	about	the	optimal	management	of	abdominal	aortic	aneurysms.	
	
	
Relevance	of	the	scientific	results	in	this	thesis	
This	 thesis	consists	of	 three	main	parts.	Part	one	focuses	on	the	perioperative	outcome	of	
patients	included	in	the	ENGAGE	registry.	It	describes	the	outcomes	of	a	contemporary	stent	
graft	 devices	 in	 current	 practice,	 and	 compares	 feasibility	 and	 outcome	 of	 EVAR	 with	
different	anaesthetic	modalities	and	outcome	of	EVAR	in	more	urgent	cases.		
	
With	the	fast	changing	stentgraft	designs	it	is	important	to	keep	hold	on	the	performance	of	
contemporary	 EVAR	 devices	 and	 put	 these	 results	 in	 perspective	 to	 older	 generations	 of	
devices	en	conventional	open	surgical	AAA	treatment.	Chapter	2	describes	the	performance	
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Introduction	
An	abdominal	aortic	aneurysm	(AAA)	is	a	focal	dilatation	of	the	aorta	to	at	least	1.5	times	its	
normal	 diameter.	 The	 normal	 diameter	 of	 the	 infrarenal	 aorta	 is	 approximately	 20mm,	
therefore	an	aortic	diameter	of	30mm	or	larger	is	considered	being	aneurysmatic.	AAAs	are	
a	 significant	 health	 challenge	 with	 an	 estimated	 incidence	 of	 20	 –	 40	 cases	 per	 100,000	
population	per	year.		Its	more	commonly	seen	in	men	than	in	women,	with	a	prevalence	of	
1.3%	 to	 8.9%	 in	 males	 and	 1.0%	 tot	 2.2%	 in	 females.	 The	 prevalence	 of	 AAA	 in	 The	
Netherlands	 is	 approximately	90.000	among	people	older	 than	55	years	of	age.	 Important	
risk	factors	for	the	occurrence	of	AAA	are	gender,	age	and	smoking	habits.	
	
An	AAA	 is	a	progressive	disease,	which	 if	 left	untreated	eventually	 leads	 to	 rupture	of	 the	
aneurysm	with	massive	bleeding	and	consequently	death.	To	date,	AAAs	are	responsible	for	
1.3%	 of	 all	 deaths	 among	men	 aged	 between	 65-85	 years	 in	 developed	 countries.	 In	 The	
Netherlands,	each	year	approximately	850	persons	die	of	a	ruptured	aneurysm.	Since	AAAs	
generally	exists	without	symptoms,	the	AAA	related	mortality	is	probably	underestimated.		
	
The	 risk	 of	 rupture	 increases	 with	 the	 aneurysm	 diameter.	 Initial	 treatment	 of	 an	 AAA	 is	
aimed	 at	 preventing	 rupture.	 Because	 treatment	 itself	 also	 comes	with	 a	 risk	 of	mortality	
and	morbidity,	a	selected	treatment	policy	is	constructed.	A	preventative	aneurysm	repair	is	
indicated	when	the	threshold	diameter	 is	reached	(55mm	in	men	and	52mm	in	women),	 if	
rapid	aneurysm	growth	is	observed	(>5mm	per	6	months	in	AAAs	>40mm)	or	if	the	aneurysm	
becomes	 symptomatic	 (abdominal	 or	 back	 pain).	 AAAs	 are	 responsible	 for	 approximately	
7.000	hospital	admissions	yearly	in	The	Netherlands.		
	
Two	 modalities	 of	 AAA	 treatment	 are	 available;	 conventional	 open	 surgical	 repair	 or	
minimally	 invasive	 endovascular	 repair	 (EVAR).	 In	 open	 repair	 the	 aneurysmatic	 aorta	 is	
replaced	by	a	synthetic	graft.	This	treatment	requires	laparotomy,	clamping	of	the	aorta	and	
is	 accompanied	 by	 substantial	 blood	 loss,	 and	 is	 consequently	 associated	 with	 a	
perioperative	mortality	of	2%	to	5%	and	significant	morbidity.	In	EVAR	treatment	a	synthetic	
	
	 	 	
stentgraft	 is	 fed	 from	 femoral	 artery	 access	 in	 the	 groin	 through	 the	aorta	up	 to	 the	AAA	
neck	and	subsequently	unfolded,	excluding	the	aneurysm	sac	from	blood	flow	and	pressure.	
Initially,	 EVAR	was	 considered	 to	 be	 an	 alternative	 treatment	 for	 those	 AAA	 patients	 not	
suitable	 for	 open	 repair	 due	 to	 severe	morbidities.	Meanwhile,	 EVAR	 has	 proven	 to	 be	 a	
feasible	and	safe	technique,	showing	decreased	mortality	and	morbidity	rates	compared	to	
conventional	 open	 treatment.	 EVAR	 now	 has	 become	 the	 treatment	 of	 preference	 for	
patients	with	infrarenal	AAA.				
	
Despite	the	promising	results	of	EVAR	perioperatively	and	in	the	short-term,	complications	
unique	for	endovascular	treatment	cause	EVAR	to	be	less	beneficial	in	the	longer	term.	Also,	
a	 substantial	 proportion	 (40%)	 of	 AAA	 patients	 that	 require	 repair	 fall	 outside	 stringent	
anatomic	 criteria	 that	 make	 treatment	 with	 commercially	 available	 stentgrafts	 suitable.		
Improvement	 of	 EVAR	 treatment	 is	 necessary	 to	 enhance	 outcomes	 of	 AAA	 patients.	 The	
technology	 of	 EVAR	 is	 a	 dynamic	 ever-changing	 endeavour.	 The	 challenge	 is	 to	 decrease	
complications	and	reinterventions,	while	safely	 treating	more	complex	anatomy,	especially	
those	cases	unfit	for	open	repair.	In	the	mean	time	hold	dear	to	resource-effective	strategies	
that	 do	 not	 include	 technically	 complex	 and	 costly	 interventions	 when	 they	 are	 not	
necessary.	 Both	 patients	 and	 society	 as	 a	 whole	 benefit	 from	 simply	 applicable	 and	
affordable	 techniques	 for	 AAA	 repair.	 Well-designed	 registries	 that	 closely	 monitor	 the	
performance	of	new	graft	designs	and	new	endovascular	techniques	are	therefore	crucial	in	
making	balanced	judgement	about	the	optimal	management	of	abdominal	aortic	aneurysms.	
	
	
Relevance	of	the	scientific	results	in	this	thesis	
This	 thesis	consists	of	 three	main	parts.	Part	one	focuses	on	the	perioperative	outcome	of	
patients	included	in	the	ENGAGE	registry.	It	describes	the	outcomes	of	a	contemporary	stent	
graft	 devices	 in	 current	 practice,	 and	 compares	 feasibility	 and	 outcome	 of	 EVAR	 with	
different	anaesthetic	modalities	and	outcome	of	EVAR	in	more	urgent	cases.		
	
With	the	fast	changing	stentgraft	designs	it	is	important	to	keep	hold	on	the	performance	of	
contemporary	 EVAR	 devices	 and	 put	 these	 results	 in	 perspective	 to	 older	 generations	 of	
devices	en	conventional	open	surgical	AAA	treatment.	Chapter	2	describes	the	performance	
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of	the	Endurant	Stent	Graft.		Within	the	real-world	ENGAGE	Registry	perioperative	and	one-
year	 results	 are	promising.	 Complication	 and	 reintervention	 rates	 compare	beneficial	with	
those	 reported	 in	 the	 landmark	 EVAR-1,	 DREAM	 and	 OVER	 trails.	 This	 strengthens	 the	
evidence	for	the	preferential	use	of	EVAR	over	conventional	open	surgical	repair	whenever	
AAA	treatment	is	indicated.		Chapter	3	represents	the	largest	comparative	analyses	between	
EVAR	outcome	in	symptomatic	and	asymptomatic	AAA	patients.		It	shows	that	with	the	use	
of	contemporary	devices	and	technical	proficiency	of	EVAR,	the	outcome	of	urgent	EVAR	in	
symptomatic	cases	 is	not	different	 from	the	outcome	of	elective	EVAR.	Feasibility	of	EVAR	
under	regional	or	local	anaesthesia	has	been	proven	20	years	ago,	however	there	is	still	no	
consensus	 on	 which	 type	 of	 anaesthesia	 is	 most	 suitable.	 Chapter	 4	 strengthens	 the	
evidence	 in	 favour	of	 a	 strategy	based	on	preferential	 use	of	 locoregional	 anaesthesia	 for	
EVAR.	It	shows	that	type	of	anaesthesia	used	for	EVAR	has	no	influence	on	technical	success	
and	perioperative	mortality	and	morbidity,	but	that	the	use	of	local	or	regional	anaesthesia	
appears	to	be	beneficial	concerning	procedural	time,	ICU	admission,	postoperative	hospital	
stay	and	recovery.				
	
The	focus	in	part	two	of	this	thesis	is	on	the	handling	of	the	ostium	of	the	internal	iliac	artery	
(IIA)	whenever	coverage	is	indicated.	It	questions	if	treatment	with	more	complex	solutions	
is	 really	necessary	or	 if	 iliac	 stenting	with	 the	omission	of	 coil	 embolisation	 is	 also	 safe	 to	
perform.	 A	 review	 of	 literature	 in	 Chapter	 5	 shows	 that	 so-feared	 IIA-related	 endoleaks	
following	 IIA	 stentgraft	 coverage	 without	 prior	 coil	 embolisation	 are	 rarely	 reported.	
Suggested	pre-emptive	coil	embolisation	as	a	preventative	measure	related-endoleaks	may	
therefore	be	unnecessary.	Furthermore,	results	 from	a	strategy	 in	which	stent	coverage	of	
the	 IIA	was	 routinely	performed	without	prior	 coil	 embolisation	 show	 that	 this	 strategy	 in	
EVAR	 treatment	 of	 aorto-iliac	 and	 iliac	 aneurysms	 is	 safe	 and	 effective,	 and	 may	 reduce	
complications.	 	 Chapter	 6	 confirms	 these	 conclusions	 in	 a	 comparative	 analysis	 from	 the	
ENGAGE	Registry	that	shows	that	the	omission	of	coil	embolisation	 in	case	of	 IIA	coverage	
does	not	increase	the	incidence	of	endoleaks	or	related	secondary	interventions.	Since	this	is	
the	largest	comparative	study	on	the	topic,	and	therefore	the	strongest	evidence	to	date	it	
may	imply	abandoning	of	pre-emptive	coil	embolisation	as	a	standard	regimen.		
	
	
	 	 	
In	part	three	of	this	thesis	an	overview	is	given	on	the	current	management	and	prevention	
of	complications	that	are	unique	for	EVAR.	Chapter	7	describes	the	evolution	of	occurrence	
and	 treatment	 options	 of	 all	 types	 of	 endoleaks,	 device	 migration,	 stent	 fractures,	 graft	
detoriation,	 or	 even	 persistent	 aneurysm	 growth	 that	 EVAR	 patients	 may	 experience.	
Advanced	 stent	 graft	 designs	 and	 increased	 understanding	 of	 management	 of	 these	
technical	 complications	 are	 declining	 the	 incidence	 rate	 for	 the	 necessity	 of	 secondary	
interventions,	which	is	considered	the	down-side	of	EVAR	and	matter	of	great	concern	in	the	
landmark	 trials	 that	 compare	 EVAR	 with	 open	 repair.	 Furthermore,	 in	 Chapter	 8	 a	 study	
design	is	presented	to	give	more	insight	in	the	outcome	of	EVAR	with	contemporary	devices	
in	patients	with	challenging	AAA	morphology.				
	
	
Innovation	and	future	
Randomized	 controlled	 trials	 (RCTs)	 are	 considered	 the	 gold	 standard	 in	 the	 hierarchy	 of	
research	designs	for	evaluating	the	efficacy	and	safety	of	a	treatment	 intervention.	Results	
of	 RCTs,	 however,	 may	 not	 reflect	 ‘real	 world’	 since	 patient	 inclusion	 is	 subject	 to	 strict	
criteria,	and	can	therefore	have	limited	applicability	to	individual	patients	in	clinical	setting.	
Moreover,	one	must	question	if	RCT	design	is	feasible	in	qualifying	outcome	of	EVAR	in	view	
of	 the	 contemporary	 preference	 for	 EVAR	 and	 the	 swift	 evolution	 in	 stent	 graft	 designs.	
Large	high-quality,	well-designed	observational	studies	are	 increasingly	believed	to	provide	
complementary	 evidence	 to	 RCTs.	 They	 can	 assess	 treatment	 effectiveness	 in	 patients	
encountered	 in	 day-to-day	 clinical	 practice	 because	 of	 the	 use	 of	 larger	 and	 more	
heterogeneous	 populations	 with	 common	 comorbidities	 and	 longer	 follow-up	 periods.	 A	
mandatory	registry	on	AAA-treatment	that	is	globally	supported	by	doctors	and	is	financially	
supported	governments	and	 industries	might	be	 the	solution	 for	creating	a	benchmark	 for	
future	treatment	and	qualifying	performance	of	new	devices.		
	
This	thesis	and	future	research	contributes	to	the	understanding	of	AAA	treatment	and	the	
development	 of	 national	 and	 international	 guidelines	 that	 give	 guidance	 to	 the	 optimal	
treatment	of	abdominal	 aortic	 aneurysms.	Above	all	making	AAA	disease	a	 less	 lethal	 and	
more	bearable	disease.	
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AAA	treatment	is	indicated.		Chapter	3	represents	the	largest	comparative	analyses	between	
EVAR	outcome	in	symptomatic	and	asymptomatic	AAA	patients.		It	shows	that	with	the	use	
of	contemporary	devices	and	technical	proficiency	of	EVAR,	the	outcome	of	urgent	EVAR	in	
symptomatic	cases	 is	not	different	 from	the	outcome	of	elective	EVAR.	Feasibility	of	EVAR	
under	regional	or	local	anaesthesia	has	been	proven	20	years	ago,	however	there	is	still	no	
consensus	 on	 which	 type	 of	 anaesthesia	 is	 most	 suitable.	 Chapter	 4	 strengthens	 the	
evidence	 in	 favour	of	 a	 strategy	based	on	preferential	 use	of	 locoregional	 anaesthesia	 for	
EVAR.	It	shows	that	type	of	anaesthesia	used	for	EVAR	has	no	influence	on	technical	success	
and	perioperative	mortality	and	morbidity,	but	that	the	use	of	local	or	regional	anaesthesia	
appears	to	be	beneficial	concerning	procedural	time,	ICU	admission,	postoperative	hospital	
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The	focus	in	part	two	of	this	thesis	is	on	the	handling	of	the	ostium	of	the	internal	iliac	artery	
(IIA)	whenever	coverage	is	indicated.	It	questions	if	treatment	with	more	complex	solutions	
is	 really	necessary	or	 if	 iliac	 stenting	with	 the	omission	of	 coil	 embolisation	 is	 also	 safe	 to	
perform.	 A	 review	 of	 literature	 in	 Chapter	 5	 shows	 that	 so-feared	 IIA-related	 endoleaks	
following	 IIA	 stentgraft	 coverage	 without	 prior	 coil	 embolisation	 are	 rarely	 reported.	
Suggested	pre-emptive	coil	embolisation	as	a	preventative	measure	related-endoleaks	may	
therefore	be	unnecessary.	Furthermore,	results	 from	a	strategy	 in	which	stent	coverage	of	
the	 IIA	was	 routinely	performed	without	prior	 coil	 embolisation	 show	 that	 this	 strategy	 in	
EVAR	 treatment	 of	 aorto-iliac	 and	 iliac	 aneurysms	 is	 safe	 and	 effective,	 and	 may	 reduce	
complications.	 	 Chapter	 6	 confirms	 these	 conclusions	 in	 a	 comparative	 analysis	 from	 the	
ENGAGE	Registry	that	shows	that	the	omission	of	coil	embolisation	 in	case	of	 IIA	coverage	
does	not	increase	the	incidence	of	endoleaks	or	related	secondary	interventions.	Since	this	is	
the	largest	comparative	study	on	the	topic,	and	therefore	the	strongest	evidence	to	date	it	
may	imply	abandoning	of	pre-emptive	coil	embolisation	as	a	standard	regimen.		
	
	
	 	 	
In	part	three	of	this	thesis	an	overview	is	given	on	the	current	management	and	prevention	
of	complications	that	are	unique	for	EVAR.	Chapter	7	describes	the	evolution	of	occurrence	
and	 treatment	 options	 of	 all	 types	 of	 endoleaks,	 device	 migration,	 stent	 fractures,	 graft	
detoriation,	 or	 even	 persistent	 aneurysm	 growth	 that	 EVAR	 patients	 may	 experience.	
Advanced	 stent	 graft	 designs	 and	 increased	 understanding	 of	 management	 of	 these	
technical	 complications	 are	 declining	 the	 incidence	 rate	 for	 the	 necessity	 of	 secondary	
interventions,	which	is	considered	the	down-side	of	EVAR	and	matter	of	great	concern	in	the	
landmark	 trials	 that	 compare	 EVAR	 with	 open	 repair.	 Furthermore,	 in	 Chapter	 8	 a	 study	
design	is	presented	to	give	more	insight	in	the	outcome	of	EVAR	with	contemporary	devices	
in	patients	with	challenging	AAA	morphology.				
	
	
Innovation	and	future	
Randomized	 controlled	 trials	 (RCTs)	 are	 considered	 the	 gold	 standard	 in	 the	 hierarchy	 of	
research	designs	for	evaluating	the	efficacy	and	safety	of	a	treatment	 intervention.	Results	
of	 RCTs,	 however,	 may	 not	 reflect	 ‘real	 world’	 since	 patient	 inclusion	 is	 subject	 to	 strict	
criteria,	and	can	therefore	have	limited	applicability	to	individual	patients	in	clinical	setting.	
Moreover,	one	must	question	if	RCT	design	is	feasible	in	qualifying	outcome	of	EVAR	in	view	
of	 the	 contemporary	 preference	 for	 EVAR	 and	 the	 swift	 evolution	 in	 stent	 graft	 designs.	
Large	high-quality,	well-designed	observational	studies	are	 increasingly	believed	to	provide	
complementary	 evidence	 to	 RCTs.	 They	 can	 assess	 treatment	 effectiveness	 in	 patients	
encountered	 in	 day-to-day	 clinical	 practice	 because	 of	 the	 use	 of	 larger	 and	 more	
heterogeneous	 populations	 with	 common	 comorbidities	 and	 longer	 follow-up	 periods.	 A	
mandatory	registry	on	AAA-treatment	that	is	globally	supported	by	doctors	and	is	financially	
supported	governments	and	 industries	might	be	 the	solution	 for	creating	a	benchmark	 for	
future	treatment	and	qualifying	performance	of	new	devices.		
	
This	thesis	and	future	research	contributes	to	the	understanding	of	AAA	treatment	and	the	
development	 of	 national	 and	 international	 guidelines	 that	 give	 guidance	 to	 the	 optimal	
treatment	of	abdominal	 aortic	 aneurysms.	Above	all	making	AAA	disease	a	 less	 lethal	 and	
more	bearable	disease.	
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